Comparison of calcium-binding proteins expressed in cultured hNT neurons and hNT neurons transplanted into the rat striatum.
An alternative source of cells for neural transplantation and brain repair that has many characteristics of immature neurons is the hNT neuron, derived from an embryonal human teratocarcinoma (NTera2) cell line that is terminally differentiated in vitro with retinoic acid. The majority of hNT neurons are GABAergic in cell culture. We have determined the calcium-binding protein (CBP) phenotypes of hNT neurons for three CBPs, calretinin (CR), calbindin D-28K (CB), and parvalbumin (PV), in cell culture and after transplantation into the rat striatum. In cell culture, 95% of all cell profiles were human nuclear matrix antigen (NuMA) positive. PV-positive hNT neurons constituted 50% of all neuron-like profiles, with CB+ and CR+ constituting 14 and 6% of cells, respectively. In contrast, when the striatal grafts were examined after 30 days survival using confocal microscopy, only 10% of hNT neurons immunopositive for NuMA were PV+; 19% were CB+/NuMA+, approximately the same percentage as was seen in vitro, and 82% of grafted hNT neurons were CR+. These results suggest that hNT neurons can be subdivided into at least three subpopulations based on the CBP phenotype that they express and that there is a CBP phenotypic shift following transplantation. Three related hypotheses are proposed to account for this phenotypic shift of hNT neurons after transplantation: (a) selective survival of the CR+ subpopulation of hNT neurons, (b) selective transitory quiescence of the transplanted PV+ cells due to transplantation stress, or (c) dedifferentiation of the hNT neurons following transplantation, which may allow them to respond to local environmental cues during the engraftment process.
Saporta
S
S
Department of Anatomy, University of South Florida School of Medicine, Tampa, Florida 33612, USA.
Willing
A E
AE
Zigova
T
T
Daadi
M M
MM
Sanberg
P R
PR
D000818:Animals; D034961:Antigens, Nuclear; D016380:Brain Tissue Transplantation / Q000379:methods; D002135:Calcium-Binding Proteins / Q000096:biosynthesis*; D018797:Cell Cycle Proteins; D002454:Cell Differentiation / Q000187:drug effects; D002478:Cells, Cultured; D003342:Corpus Striatum / Q000473:pathology / Q000601:surgery*; D015925:Cryopreservation; D054278:Embryonal Carcinoma Stem Cells; D005260:Female; D016332:Fetal Tissue Transplantation / Q000379:methods; D006085:Graft Survival; D006801:Humans; D014411:Neoplastic Stem Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism / Q000637:transplantation*; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism / Q000637:transplantation*; D034521:Nuclear Matrix-Associated Proteins; D009687:Nuclear Proteins / Q000096:biosynthesis; D010641:Phenotype; D051381:Rats; D017207:Rats, Sprague-Dawley; D020521:Stroke / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D018243:Teratocarcinoma; D014183:Transplantation, Heterologous; D014212:Tretinoin / Q000494:pharmacology; D014446:Tyrosine 3-Monooxygenase / Q000096:biosynthesis
D034961:Antigens, Nuclear; D002135:Calcium-Binding Proteins; D018797:Cell Cycle Proteins; C050045:NUMA1 protein, human; D034521:Nuclear Matrix-Associated Proteins; D009687:Nuclear Proteins; C489081:Numa1 protein, rat; D014212:Tretinoin; D014446:Tyrosine 3-Monooxygenase